Critical Deadline Approaches for Aardvark Therapeutics Investors Facing Substantial Losses

Aardvark Therapeutics Class Action Lawsuit Notification

As the clock ticks down towards a critical deadline, investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) are being urged to take immediate legal action following significant financial losses. Hagens Berman Sobol Shapiro LLP, a recognized firm specializing in shareholder rights, has brought attention to the impending securities class action lawsuit that could provide restitution for affected investors.

Understanding the Situation

The lawsuit pertains to individuals who acquired common stock in Aardvark either through its initial public offering on February 13, 2025, or during the subsequent trading period up until May 14, 2026. The firm is calling upon these investors, particularly those who suffered losses due to misleading statements made by Aardvark regarding its main product, ARD-101.

The lawsuit claims that Aardvark's offering documents misrepresented the safety and efficacy of ARD-101, which is intended to treat hyperphagia in patients with Prader-Willi Syndrome. Allegations include that Aardvark's management failed to disclose critical safety data regarding the drug during clinical trials, which led to an inflated perception of its clinical prospects.

Key Allegations

Among the significant claims are the following:
1. Misleading Safety Claims: Investors were not informed of considerable safety concerns associated with ARD-101, particularly reversible cardiac observations generated from trial data.
2. Trial Results Overstatement: There were assertions that Aardvark's Phase 3 HERO trial and associated regulatory prospects were overstated, reinforcing investor confidence without the backing of factual data.
3. Consequential Stock Price Drop: Following a voluntary pause of its HERO trial announced on February 27, 2026, due to safety concerns, Aardvark's stock price fell sharply by over 56%. Later, on May 14, the FDA imposed a clinical hold on the drug, triggering an additional 32.1% drop in stock value.

Important Deadlines

Investors affected by these developments must act quickly. The lead plaintiff motion deadline is set for October 13, 2026. Those eligible can seek to represent the class in the lawsuit against Aardvark, providing a potential pathway for financial recovery.

Hagens Berman is inviting all Aardvark investors to connect with their legal team to discuss their rights and explore possible avenues for recovery. Investors are encouraged to gather any documentation related to their purchases and share their experiences.

How to Proceed

Interested investors can reach out to Hagens Berman via email at [email protected] or by calling 844-916-0895 to learn more about their eligibility as a lead plaintiff. This outreach can be critical for formulating a strong case against Aardvark based on their misleading conduct.

The firm is not only focusing on current investors but is also calling out to whistleblowers who have pertinent, non-public information regarding Aardvark's practices. Under SEC regulations, these whistleblowers may qualify for rewards should their information lead to a successful recovery in this case.

About Hagens Berman

Hagens Berman is a well-established plaintiffs' rights firm recognized for its commitment to corporate accountability. The firm has secured over $2.9 billion on behalf of clients due to corporate misconduct. They have extensive team experience advocating for investors, workers, and consumers—demonstrating a clear track record in complex litigation cases.

Investors and prospective whistleblowers are accordingly encouraged to pursue this opportunity and be vigilant in protecting their rights.

For more updates and to keep informed about the investigation, potential claimants can follow Hagens Berman on social media or visit their website.